Diebold Nixdorf, Incorporated reported $3.87B of revenue over the trailing twelve months, +5.4% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $3.87B (to Q2 2026). Net income: $111M, trailing twelve months to Q2 2026. Operating margin: 6.3%, trailing twelve months to Q2 2026. EPS: $3.03, trailing twelve months to Q2 2026.

DBDDiebold Nixdorf, Incorporated

Technology

$63.68+12% 1Y

$63.68

$54.9052 weeks$90.72

DBD as reported

Diebold Nixdorf, Incorporated reported $3.87B of revenue over the trailing twelve months, +5.4% on the year before. 11 reported series are charted on this page, each one as filed.

$3.87B

Revenue, trailing twelve months · to Q2 2026 · +5.4% against the twelve months before

Net income: $111M
Net income · −962% year on year · trailing twelve months to Q2 2026
Operating margin: 6.3%
Operating margin · trailing twelve months to Q2 2026
EPS: $3.03
EPS · −991% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for DBD, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$3.87B	+5.4%	Q2 2026
Net income	$111M	−962%	Q2 2026
EPS	$3.03	−991%	Q2 2026
Gross margin	25%	n/a	Q2 2026
Operating margin	6.3%	n/a	Q2 2026
Net margin	2.8%	n/a	Q2 2026
ROE	8.8%	n/a	Q2 2026
ROA	2.4%	n/a	Q2 2026
ROIC	11%	n/a	Q2 2026
Free cash flow	−$23M	n/a	Q4 2020 · 22 quarters behind
P/E	21.0	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.